Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (103)

« Back to Publications

Molecular-level observation of the self-assembly of a virus-like particle

Asor R. et al, (2026)

Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses.

Munro J. et al, (2025)

Translocating shRNA: a novel approach to RNA interference with Newcastle disease virus as viral vector.

Koh WC. et al, (2025), J Gen Virol, 106

Changes in Population Immunity to Omicron SARS-CoV-2 Variants and Selected Sarbecoviruses From 2020 to 2023 in Urban Colombo, Sri Lanka.

Bary F. et al, (2025), J Med Virol, 97

Determination of resilience of a panel of broadly neutralizing mAbs to emerging variants of SARS-CoV-2 generated using reverse genetics.

Afzal M. et al, (2025), iScience, 28

Publisher Correction: The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Huhn A. et al, (2025), Nat Commun, 16

A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.

Sadler HL. et al, (2025), J Virol, 99

Development of a recombinant non-replicating Newcastle disease virus.

Cheow P-S. et al, (2025), Avian Pathol, 54, 149 - 157

The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Huhn A. et al, (2025), Nat Commun, 16

Single-cycle, pseudotyped reporter influenza virus to facilitate evaluation of treatment strategies for avian influenza, Ebola and other highly infectious diseases in vivo.

Tan TK. et al, (2025), Front Immunol, 16

The magnitude and cross reactivity of SARS-CoV-2 specific antibody responses in Sri Lankan children and association with the nutritional status

Jeewandara C. et al, (2025)

Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses.

Hills RA. et al, (2024), Nat Nanotechnol, 19, 1216 - 1223

The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.

Chen X. et al, (2024), PLoS Pathog, 20

Changes in population immunity to omicron SARS-CoV-2 variants and selected Sarbecoviruses from 2020 to 2023 in urban Colombo, Sri Lanka

Bary F. et al, (2024)

A locally administered single cycle influenza vaccine expressing a non-fusogenic stabilised haemagglutinin stimulates strong T-cell and neutralising antibody immunity

Sadler H. et al, (2024)

Load More

1
2
3
4
5
6
7